9110 Katy Freeway,
Houston,
TX
77055
-
About the Provider
-
Education & Board Certification
-
Professional Associations
Mohammed Qureshi, MD, attended Texas Tech University Health Sciences Center School of Medicine, earning his medical degree in 2014. He then completed his residency at the Texas Tech University Health Sciences Center at the Permian Basin in 2017, followed by a fellowship at Houston Methodist Hospital in Endocrinology, Diabetes and Metabolism in 2019. Dr. Qureshi was in private practice in the Houston area for 4 years prior to joining Kelsey-Seybold.
At Kelsey-Seybold, Dr. Qureshi sees patients for diabetes mellitus (Type 1 and 2), as well as thyroid diseases like Grave's disease, Hashimoto's disease and thyroid cancer, hypogonadism, PCOS, osteoporosis, and parathyroid, pituitary, and adrenal diseases (including Cushing's and adrenal insufficiency). Dr. Qureshi joined Kelsey-Seybold in 2023.
Awards & Publications
Awards
- Resident Teaching Award 2017 for providing training and educational support for junior residents during residency training (2016 – 2017)
- Resident of the Year 2015-2016 during Post Graduate Year 2 (PGY2) at Texas Tech University HSC
- First place at Texas chapter of American College of Physicians (ACP) regional competition for oral presentation on High Dose Insulin Euglycemia Therapy
- Selected to serve as chief medical resident during final year of residency
Publications
- Methodist DeBakey Cardiovascular Journal; Vol. 14, No. 4. “Update on management of T2DM for cardiologist”
Presentations
- April 2019 - Presentation at the American Association of Clinical Endocrinologists (AACE)
- Topic: Osteitis Fibrosa Cystica: revisiting an exceedingly rare presentation of primary hyperparathyroidism
- March 2019 - Presentation at Endocrine Society 2019 meeting
- Topic: Endocrine related complications from novel immune check point inhibitors: Pembrolizumab induced Diabetic Ketoacidosis
- Oct. 2018 Presentation at 88th meeting of the American Thyroid Association (ATA)
- Topic: Restoring RAI Uptake in Metastatic BRAF V600E+ Papillary thyroid carcinoma with Dabrafenib
- Aug. 2018 Presentation at Endocrine Society’s Osteoporosis and Metabolic Bone Disease Conference - Santa Fe, NM
- Topic: Tumor Induced Osteomalacia: a rare metabolic bone disease
- Nov 2016 Presentation at Texas chapter of ACP (American College of Physicians)
- Topic: High dose Insulin Euglycemia Therapy (HIET)
Research Experience
Clinical Trials at FDA designated research site from 7/2019 to 10/2023:
- (ZEUS TRIAL) - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation. Protocol Number EX6018-4758 Phase 3a
- (SURMOUNT-2 TRIAL) Efficacy and Safety of Tirzepatide Once Weekly in Participants with Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial. Protocol Number I8F-MCOPHL Phase 3.
- (ONWARDS 2 TRIAL) A 26-week trial comparing the effect and safety of once weekly insulin Icodec and once daily insulin Degludec, both with or without noninsulin anti-diabetic drugs, in subjects with type 2 diabetes treated with basal insulin. Protocol Number NN1436-4478 Phase 3a,
- (ONWARDS 6 TRIAL) A 26-week, randomized, multicenter, open-label, active controlled, parallel group, two armed, treat-to-target trial investigating the effect on glycemic control and safety of treatment with once weekly insulin Icodec compared to once daily insulin Degludec, both in combination with insulin Aspart in adults with type 1 diabetes, with a 26-week extension investigating long term safety. Protocol Number N1436-4625 Phase 3a
- (COMBINE 3 TRIAL) A 52-week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units/mL combined with insulin apart, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily basal insulin. Protocol Number NN1535-4593 Phase 3a.
- (GRADIENT TRIAL): A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy of Relacorilant. Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia. Protocol Number CORT125134-456.
- (GRACE TRIAL): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant. Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome. Protocol Number OORT125134-455.
Hobbies & Interests
Dr. Qureshi is an enthusiastic movie fan, but he also enjoys staying active by running and playing basketball. He also likes to travel and try new foods, whether at home or away.
Education
- Texas Tech University Health Sciences Center School of Medicine, 2014
Internship/Residency
- Texas Tech University Health Sciences Center at the Permian Basin, 2017
Board Certifications
- American Board of Internal Medicine - Endocrinology; Diabetes; Metabolism
Dr. Qureshi is a member of the American Association of Clinical Endocrinologists, the Endocrine Society, the American Thyroid Association, the American College of Physicians, and the Harris County Medical Society/Texas Medical Association.
Locations
Memorial City Clinic
929 Gessner Road, Suites 1450 and 1600,
Houston,
TX
77024